Do Wall Street Analysts Like Baxter International Stock?
Baxter International (BAX) reported Q2 FY2026 results on July 30, with worldwide sales up 5% to $2.96 billion and adjusted EPS of $0.56, helped by a $0.11 per-share IEEPA tariff refund. The company raised FY2026 guidance to 3% to 4% reported sales growth and adjusted EPS of $1.95 to $2.15. Analysts’ consensus remains Hold; TD Cowen raised its price target to $24.
How this was made
%252FBaxter%252520sign%252520on%252520the%252520building%252520in%252520Mississauga%25252C%252520Ontario_%252520Baxter%252520International%252520Inc_%252520By%252520JHVEPhoto.jpeg&w=3840&q=75)
The 30-second read
Why it matters
Baxter’s Q2 beat and raised full-year outlook are the actionable catalysts, but the article also highlights that consensus expects FY2026 EPS to decrease, which can cap upside and keep the Street cautious.
Market read
Traders can reassess near-term expectations after the guidance raise, but should weigh the tariff-refund contribution and the still-cautious consensus stance.
What to watch
Analysts still expect FY2026 EPS to decline 15.4%, and the consensus remains a Hold despite the price-target raise, implying limited upside conviction.
Background
The piece frames Baxter’s relative performance versus the S&P 500 and the IHI medical devices ETF, then ties it to its July 30 Q2 FY2026 earnings and guidance changes.
Ticker impact
Baxter reported Q2 FY2026 results that beat its own revenue and earnings guidance, and raised full-year sales and EPS outlook.
Likely near-term bid on guidance raise, with follow-through dependent on whether FY2026 EPS decline expectation is revised.
The article cites a Q2 beat, a tariff-refund EPS benefit, and higher FY2026 reported sales and adjusted EPS guidance, while also noting analysts expect FY2026 EPS to fall 15.4% to $1.92.
Market effects
Positive read-through for medical devices and infusion/renal care demand expectations, though the article is single-company focused.
Limited, primarily US healthcare equities sentiment.
Low; guidance and tariff-refund detail is company-specific.
Counterpoint
The EPS upside may be partly driven by a one-time $0.11 per-share IEEPA tariff refund, so underlying operating momentum may be less strong than headline guidance suggests.
Key entities
- companyBaxter International Inc.
Reported Q2 FY2026 results, exceeded its own guidance, and raised full-year 2026 reported and organic sales growth and adjusted EPS guidance.
- analyst_firmTD Cowen
Reiterated a Hold rating and raised its price target to $24 from $20.
- ETFiShares U.S. Medical Devices ETF (IHI)
Used as a benchmark for relative performance versus BAX over the past year and 2026 YTD.
